How ProPacífico is improving gastric cancer pathway adherence with AI.
ProPacífico, with strategic support from BMS, uses Arkangel AI to measure cohort-wide adherence, spot screening gaps and prioritize high-risk patients.
Operated by
ProPacífico
Scale
Complete pilot cohort
Technology
Arkangel AI
Strategic ally
Coverage
Valle · Cauca · Nariño
6,530
patient charts processed end to end
436
High-risk
38%
No endoscopy
17.1%
Actionable finding
Real-time findings
High risk without endoscopy
patient #4823
Family history undocumented
#4824
Clinical pathway complete
#4825
436
reported high-risk cases
38%
high-risk patients without endoscopy on file
17.1%
of audited patients had an actionable finding
Method and limits of the reported figures
This article reports 6,530 reviewed charts and 436 high-risk cases. The source dataset, inclusion period, patient deduplication, exclusions, product version and independent adjudication are not published. Charts and unique people are not interchangeable denominators. If both counts use the same unit, 436 / 6,530 = 6.68%, rounded to 7%. The remaining 6,094 records do not establish adherence or absence of other findings.
Finding, endoscopy and completeness percentages are reported pilot results, not general performance or causal impact. Charts and dashboards are illustrative, not live patient records. Risk classification does not demonstrate reduced mortality. Ask the team for the protocol, denominators and disclosure permissions before reproducing or comparing the case.
100%
coverage over records processed in the pilot.
38%
of high-risk patients without an ordered or completed endoscopy.
17.1%
of reviewed patients had actionable findings.
32%
of gastric cancer patients globally receive NCCN-adherent treatment.
Every point represents audited patients. The orange points are the ones at risk.
In that cohort, Arkangel AI automatically classified 436 patients (7%) as high risk; finding them previously required manual chart-by-chart review.
Gastric cancer is Colombia’s top cancer killer.
Globally, it is the 5th most common cancer and the 5th leading cause of cancer death, with nearly one million new cases and 659,853 deaths in 2022. In Colombia, 8,938 new cases are reported each year (Global Cancer Observatory).
ProPacífico has been supporting a collaborative effort in Colombia’s Southwest (Valle, Cauca, and Nariño) with support from Bristol Myers Squibb (BMS) as a strategic ally. The region already has a clinical-administrative pathway for gastric cancer and a medical education strategy, but adherence in clinical practice remains a challenge.
Early detection is decisive: when cancer is identified in initial stages, the probability of survival increases significantly.
8,938
New cases per year in Colombia
Globocan 2022, Colombia fact sheet.
659,853
Global deaths in 2022
Gastric cancer is the 5th global cause of cancer death.
The pathway was clear. Measuring adherence at scale was not.
Manual audits are partial · Guidelines keep moving · Deviations have consequences.
Manual audits are partial
Teams can review samples, but most charts remain invisible until the next reporting cycle.
Guidelines keep moving
Medical evidence changes faster than operational audit capacity can scale.
Deviations have consequences
A missing endoscopy for a high-risk patient is not a data gap. It is a delayed opportunity.
A clinical intelligence layer that reads each chart against the pathway.
Arkangel AI identifies deviations in early detection, diagnosis, staging, treatment, and follow-up while keeping clinicians in control.
Ingest every chart
Structured and unstructured clinical evidence enters the audit workflow.
Compare to pathway
Arkangel AI evaluates each patient against ProPacífico’s pathway and Ministry guidance.
Prioritize action
Teams receive patient-level findings, missing variables, and pathway deviations.
Important. The solution does not replace medical judgment or automate clinical decisions. It works as an audit, detection, and clinical decision-support system. ProPacífico’s designed clinical pathway is the reference Pandora uses to identify when it is not being followed.
Complete cohort audited. Critical findings surfaced before they stayed invisible.
In that cohort, Arkangel AI automatically classified 436 patients (7%) as high risk; finding them previously required manual chart-by-chart review.
436
reported high-risk cases · 7% of the audited cohort
high-risk patients without endoscopy on file
38%
of audited patients had an actionable finding
17.1%
of gastric cancer patients globally receive NCCN-adherent treatment.
32%
6,530
patient charts processed end to end
The real size of the audited cohort
38%
high-risk patients without endoscopy on file
The most consequential detection gap
17.1%
of audited patients had an actionable finding
A concrete review queue for clinical teams
100%
100% pathway coverage
Not a quarterly sample. Every processed chart is checked against the pathway and Ministry of Health guidance.
Documentation quality became measurable.
Arkangel AI showed that general clinical documentation was strong, while risk variables for gastric cancer were frequently missing.
99%+
Strong general documentation signals.
~32%
Critical risk variables often missing.
ProPacífico can now see pathway adherence on every chart.
Patient-level dashboards and reports expose deviations when they happen.
High-risk patients without protocol-required endoscopy are visible and actionable.
Documentation gaps become targeted education and quality-improvement work.
×Ready to audit every chart, not just a sample?
See how Arkangel AI turns every chart into an evidence-checked pathway review, with clinicians in control.